Monkey Recombinant Proteins

OBJECTIVE KH902 is a fusion protein that combines the ligand binding elements derived from the extracellular domain of vascular endothelial growth factor (VEGF) receptors 1 and 2 and the Fc portion of IgG1. This study was designed t o test the Cat Recombinant Proteins  inhibitory effect of KH902 in a monkey model of choroidal neovascularization (CNV). METHOD Affinity binding to VEGF was measured using ELISA kits of human VEGF, and the effect of the biological activity of KH902 tested by in vitro inhibition experiments on human umbilical vein endothelial cell proliferation induced by VEGF.  The experimental CNV induced by laser injury perimacular cause in the eyes of rhesus monkeys and confirmed by fluorescence fundus angiography (FFA), optical coherence tomography (OCT) and multifocal Electroretinograms (mf-ERG) 20 days after suffering from injury Laser. KH902 delivered to the animal via intravitreal injection at various doses. The monkeys were observed four weeks after injec...

In this study, we evaluated the capacity of neutralizing antibodies induced by dengue virus types 1 and 2 envelope domain III of recombinant proteins in monkeys against a different strain of dengue virus t ypes 1 and 2 genotype. Here Swine Recombinant Proteins  we show that the dengue virus types 1 and 2 recombinant protein induced high titers of antibodies to strains of different genotypes. Organ uptake in the brain and in Vivo Rhesus monkeys of recombinant Iduronidase Compared with Insulin Receptor Antibody-Iduronidase Fusion Protein. Mucopolysaccharidosis type I (MPsi) is caused by mutations in the gene encoding the lysosomal enzyme, α-L-iduronidase (IDUA), and patients with MPsi currently being treated with IDUA enzyme replacement therapy (ERT). However, the majority of patients MPsi have severe CNS involvement, and conventional ERT did not treat brain. ERT failure to treat the brain believed to be due to the lack of transport IDUA through the blood-brain barrier (BBB). Howev...

BACKGROUND Persistent infection with high-risk human papillomavirus (HPV) is the main cause of cervical cancer, HPV16 and HPV18 and occurs in 50% and 20% of cases of cervical cancer, respectively. The viral oncogenes E6 and E7 which is Rabbit Recombiant Proteins  constitutively expressed by tumor cells related to HPV and can therefore be used as a target antigen for immunotherapy. In this study, we constructed a recombinant vaccinia virus co-expressing HPV16 / 18 E7E6 fusion proteins (rVVJ16 / 18E7E6) to be used as a therapeutic vaccine for the treatment of cancer HPV16⁺ and HPV18⁺. METHOD We construct a recombinant vaccinia virus expressing bivalent modified E7E6 fusion proteins of HPV types 16 and 18 (rVVJ16 / 18E7E6) based on vaccinia virus Tiantan strain. We then define the cellular immune response against the virus in mice and rhesus monkeys and assessed the antitumor efficacy of this response in mice using TC-1 tumor challenge models. RESULTS Our data show that rVVJ16 / 18E7E...

BACKGROUND Prophylaxis of hemophilia B, at this time, requires several infusions of human factor (F) IX concentrates per week. A FIX molecule with a prolonged half-life have the potential to further increase comfort, and compliance with, prophylaxis. OBJECTIVE The aim of our study was to investigate the pharmacokinetics (PK) and pharmacodynamic (PD) profile of the  recombinant fusion protein  linking Horse Recombinant Protein   coagulation FIX albumin (RIX-FP). METHOD Cynomolgus monkeys and dogs with hemophilia B received a single intravenous dose of Rix-FP (50-500 IU kg (-1)). RIX-FP plasma levels determined by assay based activity (dogs only) and anti-FIX ELISA method. In addition, activated partial thromboplastin time (APTT) were determined in dogs with hemophilia B. The data compared with the comparative study of direct (recombinant FIX [rFIX]) or previously published data. RESULTS Rix-FP terminal half-life prolonged in both species compared with reference data F...

Human respiratory syncytial virus (RSV) is a common cause of severe respiratory illness in infants, immunocompromised individuals, and the elderly. There is no licensed vaccine is currently available. In this study, we evaluated two Feline Recombinant Proteins  parainfluenza virus 5 (PIV5) -vectored vaccine expressing RSV F (PIV5 / F) or G (PIV5 / G) protein in cotton rats and African green monkey models for their replication, immunogenicity, and efficacy of protection against RSV challenge. After a single intranasal inoculation, both species of animals shedding virus vaccine for a limited time but without any clinical symptoms appear. In the cotton rat, causing RSV vaccine F- or G-specific serum antibodies and lung given complete protection against RSV challenge at doses as low as 103 PFU. The vaccine is not produced improved lung pathology was observed in animals immunized with a formalin-inactivated RSV.  In African green monkeys, the vaccine-induced serum and mucosal anti...